Cyclacel Pharmaceuticals (CYCC) Institutional Ownership $8.89 -0.01 (-0.11%) Closing price 04:00 PM EasternExtended Trading$8.79 -0.10 (-1.17%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Cyclacel Pharmaceuticals (NASDAQ:CYCC)CurrentInstitutional OwnershipPercentage23.58%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$98.27MNumber ofInstitutional Sellers(last 12 months)0 Get CYCC Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclacel Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYCC Institutional Buying and Selling by Quarter Cyclacel Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/15/2025Armistice Capital LLC1,269,485$354K0.0%+118.7%0.612% 8/15/2024Armistice Capital LLC134,000$217K0.0%N/A9.178% 5/10/2024 Acadian Asset Management LLC14,285$29K0.0%-41.0%1.084% 11/1/2022Kestra Advisory Services LLC23,000$34K0.0%N/A0.183% 10/25/2022Raymond James Financial Services Advisors Inc.20,806$30K0.0%-32.5%0.166% 10/18/2022McIlrath & Eck LLC26,342$38K0.0%N/A0.210% 8/15/2022Sio Capital Management LLC454,355$491K0.2%+7.5%4.546% 2/10/2022 Acadian Asset Management LLC23,242$89K0.0%N/A0.233% 11/16/2021Two Sigma Advisers LP121,500$640K0.0%+929.7%1.316% 11/15/2021Pura Vida Investments LLC105,141$554K0.0%-33.2%1.139% Get the Latest News and Ratings for CYCC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/2021Tri Locum Partners LP522,943$2.76M1.1%+66.9%5.663% 11/12/2021Affinity Asset Advisors LLC400,000$2.11M0.5%+5.3%4.332% 11/2/2021Raymond James Financial Services Advisors Inc.10,006$53K0.0%-83.3%0.108% 10/15/2021NEXT Financial Group Inc14,752$77K0.0%+70.0%0.160% 8/18/2021Ikarian Capital LLC100,000$593K0.0%-66.7%1.083% 8/17/2021Boothbay Fund Management LLC10,545$62K0.0%-66.7%0.114% 8/17/2021Citadel Advisors LLC250,797$1.49M0.0%-14.7%2.716% 8/16/2021Tri Locum Partners LP313,331$1.86M0.6%+6.8%3.393% 8/16/2021Schonfeld Strategic Advisors LLC102,525$607K0.0%-25.0%1.110% 8/16/2021Maven Securities LTD234,500$1.43M0.1%-6.2%2.540% 8/13/2021Northern Trust Corp14,957$89K0.0%N/A0.162% 8/13/2021 Geode Capital Management LLC50,860$301K0.0%+143.3%0.551% 8/13/2021 Vanguard Group Inc.327,658$1.94M0.0%+9.2%3.548% 7/31/2021NEXT Financial Group Inc8,680$51K0.0%N/A0.094% 5/19/2021Squarepoint Ops LLC23,836$169K0.0%N/A0.258% 5/18/2021Morgan Stanley100,000$711K0.0%-13.0%1.083% (Data available from 1/1/2016 forward) CYCC Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYCC shares? During the previous two years, the following institutional investors and hedge funds held shares of Cyclacel Pharmaceuticals shares: Armistice Capital LLC ($354K), Acadian Asset Management LLC ($29K).Learn more on Cyclacel Pharmaceuticals' institutional investors. What percentage of Cyclacel Pharmaceuticals' stock is owned by institutional investors? 23.58% of Cyclacel Pharmaceuticals' stock is owned by institutional investors. Learn more on CYCC's institutional investor holdings. Which institutional investors have been buying Cyclacel Pharmaceuticals' stock? The following institutional investors have purchased Cyclacel Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($823.02K). How much institutional buying is happening at Cyclacel Pharmaceuticals? Institutional investors have bought a total of 823,024 shares in the last 24 months. This purchase volume represents approximately $98.27M in transactions. Related Companies INmune Bio Institutional Ownership Biomea Fusion Institutional Ownership MiNK Therapeutics Institutional Ownership InflaRx Institutional Ownership DURECT Institutional Ownership Barinthus Biotherapeutics Institutional Ownership Cue Biopharma Institutional Ownership ImmuCell Institutional Ownership Unicycive Therapeutics Institutional Ownership Telomir Pharmaceuticals Institutional Ownership This page (NASDAQ:CYCC) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access